Status:
COMPLETED
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
Lead Sponsor:
Amicus Therapeutics
Conditions:
Fabry Disease
Eligibility:
All Genders
16-74 years
Phase:
PHASE3
Brief Summary
Study to compare the efficacy and safety of migalastat and enzyme replacement therapy (ERT) in male and female participants with Fabry disease who are currently receiving ERT and who have an alpha gal...
Detailed Description
This was a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of 150 milligrams (mg) of migalastat hydrochloride (migalastat) (equivalent to 123 mg of migalas...
Eligibility Criteria
Inclusion
- Male or female between the ages of 16 and 74 diagnosed with Fabry disease
- Confirmed α Gal-A mutation that is amenable to migalastat, based on the clinical trial HEK assay
- Participant has been on ERT for at least 12 months before screening/baseline
- Dose level and regimen of ERT have been stable for 3 months before screening/baseline and is at least 80% of the currently labeled dose and regimen for this time period
- Glomerular filtration rate (GFR) ≥ 30 milliliter (mL)/minute (min) /1.73 m\^2
- Participants taking angiotensin converting enzyme inhibitors or angiotensin receptor blockers must be on a stable dose for at least 4 weeks before screening/baseline
- Women who can become pregnant and all men agree to be sexually abstinent or use medically accepted methods of birth control throughout the duration of the study and for up to 30 days after last dose of study medication
- Participant is willing and able to provide written informed consent and assent if applicable
Exclusion
- Participant has undergone, or is scheduled to undergo, kidney transplantation or any other solid organ transplantation
- Participant is on regular dialysis that is specifically for the treatment of chronic kidney disease
- Participant has had a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within the 3 months before screening/baseline
- Participant has clinically significant unstable cardiac disease in the opinion of the investigator (for example, cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or New York Heart Association (NYHA) class III or IV congestive heart failure)
- Pregnant or breast-feeding
- History of allergy or sensitivity to study medication (including excipients) or other iminosugars (for example, miglustat, miglitol)
- Participant has absolute contraindication to iohexol and/or inability to undergo iohexol GFR testing
- Participant requires treatment with Glyset® (miglitol), or Zavesca® (miglustat)
- Participant received any investigational/experimental drug, biologic or device within 30 days of screening/baseline
- Any intercurrent illness or condition that may preclude the participant from fulfilling the study requirements or suggests to the investigator that the participant may have an unacceptable risk by participating in this study
Key Trial Info
Start Date :
September 8 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2015
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT01218659
Start Date
September 8 2011
End Date
May 28 2015
Last Update
November 1 2018
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Los Angeles, California, United States, 90048
2
Aurora, Colorado, United States, 80045
3
Decatur, Georgia, United States, 30033
4
Grand Rapids, Michigan, United States, 49525